{"id":"xin-te-mie","safety":{"commonSideEffects":[{"rate":"0.1-0.5%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1-5%","effect":"Increased risk of genital mycotic infections"},{"rate":"1-5%","effect":"Increased risk of urinary tract infections"},{"rate":"1-5%","effect":"Increased risk of hypotension"},{"rate":"0.1-0.5%","effect":"Increased risk of acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, xin te mie reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is associated with several therapeutic benefits, including improved glycemic control and weight loss.","oneSentence":"Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:25.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01760109","phase":"PHASE4","title":"Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection","status":"COMPLETED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-07","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":2000},{"nctId":"NCT01897831","phase":"PHASE4","title":"Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"UNKNOWN","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":2000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["te mie jun","xin ke jun"],"phase":"marketed","status":"active","brandName":"xin te mie","genericName":"xin te mie","companyName":"Xiangbei Welman Pharmaceutical Co., Ltd","companyId":"xiangbei-welman-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes, Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}